Hims & Hers Health (HIMS) Morgan Stanley Technology, Media & Telecom Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley Technology, Media & Telecom Conference 2026 summary
2 Mar, 2026Strategic evolution and vision
Initial focus was on making treatment for stigmatized conditions accessible and raising consumer awareness, evolving to include personalized treatments and broader capabilities.
Significant investments in technology and CapEx enabled rapid expansion into new specialties and improved operational efficiency.
Leveraging data and insights from over 2.5 million subscribers to enhance personalized care and outcomes.
Future strategy emphasizes deepening personalization, leveraging technology, expanding partnerships, and international growth.
Vision is to become the default brand for health and wellness within three to five years.
Growth initiatives and market expansion
Expanded into multi-condition offerings and launched three complex specialties in six months, including low testosterone, menopausal support, and diagnostics.
Acquisitions like YourBio Health and Eucalyptus support diagnostics and international expansion.
Each new specialty is expected to reach a $100 million+ run rate, with ambitious targets of $6.5 billion revenue and $1.3 billion EBITDA by 2030.
International strategy is driven by strong domestic cash flow, successful acquisitions, and market learnings, aiming for at least $1 billion in international revenue in the next few years.
International markets are expected to follow a similar margin expansion curve as the U.S., supported by operational expertise and capital allocation.
Marketing, brand, and consumer engagement
Shifted to broader brand education, resulting in a 7-point year-over-year improvement in marketing efficiency.
Investments in brand and proactive health education are expected to yield long-term efficiency gains.
Super Bowl ad and other campaigns have driven increased traffic and engagement.
Cross-sell opportunities and diagnostics are expected to further improve marketing efficiency and consumer retention.
Latest events from Hims & Hers Health
- 2024 revenue up 69% to $1.5B, net income $126M, 2025 guidance set at $2.3–$2.4B revenue.HIMS
Q4 20248 Jul 2026 - Q2 revenue up 52% to $315.6M, net income $13.3M, 1.9M subscribers, and raised full-year guidance.HIMS
Q2 20248 Jul 2026 - 2025 revenue up 59% to $2.35B, with strong subscriber and specialty growth, and robust 2026 outlook.HIMS
Q4 20258 Jul 2026 - Q1 2026 revenue rose 4% to $608M, but net loss widened on restructuring and margin pressure.HIMS
Q1 20268 Jul 2026 - Directors, auditor, and executive compensation were approved; Q&A to be answered post-meeting.HIMS
AGM 20264 Jul 2026 - 2030 targets hinge on global expansion, specialty growth, and AI-driven platform leadership.HIMS
2026 Evercore Global TMT Conference2 Jun 2026 - Rapidly scaling personalized health platform targets $6.5B+ revenue by 2030.HIMS
Investor presentation29 May 2026 - Proxy covers director elections, auditor ratification, and executive pay, highlighting strong growth and governance.HIMS
Proxy filing28 Apr 2026 - Votes sought for nine directors, auditor ratification, and executive pay at June 2026 meeting.HIMS
Proxy filing28 Apr 2026